Cell-free epigenomes enhanced fragmentomics-based model for early detection of lung cancer

Abstract

	•Our study elucidated the regulatory relationships between epigenetic modifications and their effects on fragmentomic features.
	•Identifying epigenetically regulated genes provided a critical foundation for developing the cfDNA fragmentomics-based machine learning model.
	•The model demonstrated exceptional clinical performance, highlighting its substantial potential for translational application in clinical practice.

Keywords

cell-free DNA / early cancer screening / epigenomics / liquid biopsy / lung cancer

References

[1] BrayF, Laversanne M, SungH, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2] GoldstrawP, Chansky K, CrowleyJ, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016; 11(1): 39-51.

[3] AberleDR, AdamsAM, BergCD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395-409.

[4] ChenK, HeY, WangW, et al. Development of new techniques and clinical applications of liquid biopsy in lung cancer management. Sci Bull (Beijing). 2024; 69(10): 1556-1568.

[5] StejskalP, Goodarzi H, SrovnalJ, et al. Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance. Mol Cancer. 2023; 22(1): 15.

[6] ZhangK, FuR, LiuR, et al. Circulating cell-free DNA-based multi-cancer early detection. Trends Cancer. 2024; 10(2): 161-174.

[7] SnyderMW, Kircher M, HillAJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016; 164(1-2): 57-68.

[8] SunK, JiangP, ChengSH, et al. Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin. Genome Res. 2019; 29(3): 418-427.

[9] SerpasL, ChanRWY, JiangP, et al. Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA. Proc Natl Acad Sci USA. 2019; 116(2): 641-649.

[10] JiangP, SunK, PengW, et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation. Cancer Discov. 2020; 10(5): 664-673.

[11] ZhuD, WangH, WuW, et al. Circulating cell-free DNA fragmentation is a stepwise and conserved process linked to apoptosis. BMC Biol. 2023; 21(1): 253.

[12] MathiosD, Johansen JS, CristianoS, et al. Detection and characterization of lung cancer using cell-free DNA fragmentomes. Nat Commun. 2021; 12(1): 5060.

[13] KimJ, HongSP, LeeS, et al. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids. Hum Genomics. 2023; 17(1): 96.

[14] YotsukuraM, Asamura H, MotoiN, et al. Long-term prognosis of patients with resected adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung. J Thorac Oncol. 2021; 16(8): 1312-1320.

[15] EsfahaniMS, Hamilton EG, MehrmohamadiM, et al. Inferring gene expression from cell-free DNA fragmentation profiles. Nat Biotechnol. 2022; 40(4): 585-597.

[16] StanleyKE, Jatsenko T, TuveriS, et al. Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology. Nat Commun. 2024; 15(1): 2220.

[17] MaanssonCT, Thomsen LS, MeldgaardP, et al. Integration of cell-free DNA end motifs and fragment lengths can identify active genes in liquid biopsies. Int J Mol Sci. 2024; 25(2): 1243.

[18] LiangW, ZhaoY, HuangW, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019; 9(7): 2056-2070.

[19] LiuMC, OxnardGR, KleinEA, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020; 31(6): 745-759.

[20] SadehR, Sharkia I, FialkoffG, et al. ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin. Nat Biotechnol. 2021; 39(5): 586-598.

[21] BacaSC, SeoJH, DavidsohnMP, et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023; 29(11): 2737-2741.

[22] ZhuG, GuoYA, HoD, et al. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden. Nat Commun. 2021; 12(1): 2229.

[23] ParrenoV, Loubiere V, SchuettengruberB, et al. Transient loss of polycomb components induces an epigenetic cancer fate. Nature. 2024; 629(8012): 688-696.

[24] FialkoffG, Takahashi N, SharkiaI, et al. Subtyping of small cell lung cancer using plasma cell-free nucleosomes. bioRxiv. 2022. 2022.2006.2024.497386.

[25] Trier MaanssonC, Meldgaard P, StougaardM, et al. Cell-free chromatin immunoprecipitation can determine tumor gene expression in lung cancer patients. Mol Oncol. 2023; 17(5): 722-736.

[26] BrouwerI, Kerklingh E, van LeeuwenF, et al. Dynamic epistasis analysis reveals how chromatin remodeling regulates transcriptional bursting. Nat Struct Mol Biol. 2023; 30(5): 692-702.

[27] TolstorukovMY, SansamCG, LuP, et al. Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci USA. 2013; 110(25): 10165-10170.

[28] ChenL, Abou-Alfa GK, ZhengB, et al. Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res. 2021; 31(5): 589-592.

[29] PhamTMQ, PhanTH, JasmineTX, et al. Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer. Front Oncol. 2023; 13: 1127086.

[30] KakinumaR, Noguchi M, AshizawaK, et al. Natural history of pulmonary subsolid nodules: a prospective multicenter study. J Thorac Oncol. 2016; 11(7): 1012-1028.

[31] StackpoleML, ZengW, LiS, et al. Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer. Nat Commun. 2022; 13(1): 5566.

[32] ZhouZ, MaML, ChanRWY, et al. Fragmentation landscape of cell-free DNA revealed by deconvolutional analysis of end motifs. Proc Natl Acad Sci USA. 2023; 120(17): e2220982120.

[33] WuT, HuE, XuS, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021; 2(3): 100141.

[34] GuoS, XuZ, DongX, et al. GPSAdb: a comprehensive web resource for interactive exploration of genetic perturbation RNA-seq datasets. Nucleic Acids Res. 2023; 51(D1): D964-d968.

[35] HubbellE, ClarkeCA, AravanisAM, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev. 2021; 30(3): 460-468.

[36] HanB, ZhengR, ZengH, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024; 4(1): 47-53.

[37] ZengH, RanX, AnL, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. Lancet Public Health. 2021; 6(12): e877-e887.

[38] HeS, LiH, CaoM, et al. Survival of 7, 311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China. Transl Lung Cancer Res. 2022; 11(8): 1591-1605.

[39] LoYMD, HanDSC, JiangP, et al. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies. Science. 2021; 372(6538).

[40] MaluchenkoNV, NilovDK, PushkarevSV, et al. Mechanisms of nucleosome reorganization by PARP1. Int J Mol Sci. 2021; 22(22).

[41] BradnerJE, HniszD, YoungRA. Transcriptional addiction in cancer. Cell. 2017; 168(4): 629-643.

[42] CarterB, ZhaoK. The epigenetic basis of cellular heterogeneity. Nat Rev Genet. 2021; 22(4): 235-250.

[43] HanDSC, NiM, ChanRWY, et al. The biology of cell-free DNA fragmentation and the roles of DNASE1, DNASE1L3, and DFFB. Am J Hum Genet. 2020; 106(2): 202-214.

[44] TianXY, LiJ, LiuTH, et al. The overexpression of AUF1 in colorectal cancer predicts a poor prognosis and promotes cancer progression by activating ERK and AKT pathways. Cancer Med. 2020; 9(22): 8612-8623.

[45] ClaytonNS, RidleyAJ. Targeting Rho GTPase signaling networks in cancer. Front Cell Dev Biol. 2020; 8: 222.

[46] WeeP, WangZ. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017; 9(5): 52.

[47] FialaC, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018; 16(1): 166.

[48] MarkusH, Chandrananda D, MooreE, et al. Refined characterization of circulating tumor DNA through biological feature integration. Sci Rep. 2022; 12(1): 1928.

[49] SanchezC, RochB, MazardT, et al. Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics. JCI Insight. 2021; 6(7): e144561.

[50] CristianoS, LealA, PhallenJ, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019; 570(7761): 385-389.

[51] OberhoferA, Bronkhorst AJ, UhligC, et al. Tracing the origin of cell-free DNA molecules through tissue-specific epigenetic signatures. Diagnostics (Basel). 2022; 12(8): 1834.

[52] YangJ, XuJ, WangW, et al. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2023; 8(1): 210.

[53] FuK, BonoraG, PellegriniM. Interactions between core histone marks and DNA methyltransferases predict DNA methylation patterns observed in human cells and tissues. Epigenetics. 2020; 15(3): 272-282.

[54] GinnoPA, Gaidatzis D, FeldmannA, et al. A genome-scale map of DNA methylation turnover identifies site-specific dependencies of DNMT and TET activity. Nat Commun. 2020; 11(1): 2680.

[55] HuX, Estecio MR, ChenR, et al. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun. 2021; 12(1): 687.

[56] ZhangY, FuF, ZhangQ, et al. Evolutionary proteogenomic landscape from pre-invasive to invasive lung adenocarcinoma. Cell Rep Med. 2024; 5(1): 101358.

[57] DejimaH, HuX, ChenR, et al. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun. 2021; 12(1): 2722.

[58] LaFaveLM, KarthaVK, MaS, et al. Epigenomic state transitions characterize tumor progression in mouse lung adenocarcinoma. Cancer Cell. 2020; 38(2): 212-228.e213.

[59] HagaY, Sakamoto Y, KajiyaK, et al. Whole-genome sequencing reveals the molecular implications of the stepwise progression of lung adenocarcinoma. Nat Commun. 2023; 14(1): 8375.

[60] TanT, ShiP, AbbasMN, et al. Epigenetic modification regulates tumor progression and metastasis through EMT (Review). Int J Oncol. 2022; 60(6): 70.

[61] ChabonJJ, Hamilton EG, KurtzDM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020; 580(7802): 245-251.

[62] LiangN, LiB, JiaZ, et al. Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021; 5(6): 586-599.

[63] MazzonePJ, BachPB, CareyJ, et al. Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection. Cancer Discov. 2024; 14(11): 2224-2242.

[64] LiY, JiangG, WuW, et al. Multi-omics integrated circulating cell-free DNA genomic signatures enhanced the diagnostic performance of early-stage lung cancer and postoperative minimal residual disease. EBioMedicine. 2023; 91: 104553.

[65] ChenK, SunJ, ZhaoH, et al. Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy. Mol Cancer. 2021; 20(1): 23.

[66] SajiH, OkadaM, TsuboiM, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022; 399(10335): 1607-1617.

[67] AltorkiN, WangX, KozonoD, et al. Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. N Engl J Med. 2023; 388(6): 489-498.

[68] WangQ, SongX, ZhaoF, et al. Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram. Cancer Sci. 2023; 114(12): 4607-4621.

[69] HeJ, WangB, TaoJ, et al. Accurate classification of pulmonary nodules by a combined model of clinical, imaging, and cell-free DNA methylation biomarkers: a model development and external validation study. Lancet Digit Health. 2023; 5(10): e647-e656.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.